ABL1 F317I

CI-VAR-00001104Explore in graph →NP_005148.2:p.Phe317IleNM_005157.5:c.949T>AClinVar 376119 CIViC 1625 rs1057519773

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
BCR::ABL1 Fusion AND ABL1 F317I	Dasatinib	Predictive	C	Supports Resistance	2	submitted	EID4726 In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABLfusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, a Ph+… (full text at CIViC) PMID 17339191 · Soverini et al., 2007 · Open in CIViC	civic
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
BCR::ABL1 Fusion AND ABL1 F317I	Dasatinib	Predictive	D	Supports Resistance	1	accepted	EID6217 In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.